Result of Annual General Meeting
Rhea-AI Summary
Biodexa Pharmaceuticals (Nasdaq: BDRX)/b) announced voting outcomes from its re-scheduled Annual General Meeting held on June 30, 2026.Ordinary resolutions 1–7 passed with majorities between 73% and 94%. Ordinary resolution 8, special resolution 10, and contingent resolution 11 did not pass.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Positive
- Ordinary resolutions 1–7 approved with 73–94% shareholder majorities
- Re-scheduled Annual General Meeting successfully held on June 30, 2026
Negative
- Ordinary resolution 8 did not receive sufficient shareholder support
- Special resolution 10 failed to pass at the Annual General Meeting
- Contingent resolution 11 failed because resolution 8 was not approved
News Market Reaction – BDRX
On the day this news was published, BDRX gained 3.09%, reflecting a moderate positive market reaction. Argus tracked a peak move of +16.7% during that session. Argus tracked a trough of -16.8% from its starting point during tracking. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $70K to the company's valuation, bringing the market cap to $2.34M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 29 | Clinical trial update | Positive | -2.4% | Health Canada approved expansion of Serenta Phase 3 FAP trial into Canada. |
| Jun 17 | AGM logistics | Neutral | +1.7% | Annual General Meeting adjourned for lack of quorum and re-scheduled. |
| May 14 | Capital reorg proposal | Negative | -8.5% | Proposed 10,000:1 reverse split and share capital reorganisation for AGM vote. |
| Apr 02 | Partnership announcement | Positive | +42.2% | Partnership with Syngene to manufacture MTX240 GMP clinical trial supplies. |
| Mar 31 | Access program launch | Positive | +1.0% | Global Early Access / Named Patient Program for eRapa in FAP patients. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
BDRX has generally traded in line with news tone, with one recent divergence on a positive clinical trial update.
Regulatory & Risk Context
Reported short positioning appears relatively low, suggesting more limited short-squeeze potential and a lower contribution of short covering to volatility.
Key Terms
ordinary resolution regulatory
special resolution regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
June 30, 2026
Biodexa Pharmaceuticals PLC
(“Biodexa” or the “Company”)
Result of Annual General Meeting
Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) (“Biodexa” or “the Company”), a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers announces that its re-scheduled Annual General Meeting held at 11.00 BST today, ordinary resolutions 1 through 7 passed with majorities of
ENDS
About Biodexa Pharmaceuticals PLC
Biodexa Pharmaceuticals PLC (listed on NASDAQ: BDRX) is a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs. The Company’s lead development programs include eRapa, under development for Familial Adenomatous Polyposis and Non-Muscle Invasive Bladder Cancer, MTX240 under development for Gastrointestinal Stromal Tumors (GIST) and tolimidone, under development for the treatment of type 1 diabetes.
eRapa is a proprietary oral capsule formulation of rapamycin, also known as sirolimus. Rapamycin is an mTOR (mammalian Target Of Rapamycin) inhibitor. mTOR has been shown to have a significant role in the signalling pathway that regulates cellular metabolism, growth and proliferation and is activated during tumorigenesis.
MTX240 is a molecular glue, bringing two intracellular proteins, PDE3a and SLFN12, specifically co-expressed by GIST cancer cells, into close proximity to form a stable complex. This interaction stabilizes SLFN12, enabling it to drive RNase-mediated apoptosis in GIST cells through a mechanism independent of KIT signalling.
Tolimidone is an orally delivered, potent and selective inhibitor of Lyn kinase. Lyn is a member of the Src family of protein tyrosine kinases, which is mainly expressed in hematopoietic cells, in neural tissues, liver, and adipose tissue. Tolimidone demonstrates glycaemic control via insulin sensitization in animal models of diabetes and has the potential to become a first in class blood glucose modulating agent.
Biodexa’s headquarters and R&D facility is in Cardiff, UK. For more information visit www.biodexapharma.com.
Forward-Looking Statements
Certain statements in this announcement may constitute “forward-looking statements” within the meaning of legislation in the United Kingdom and/or United States. Such statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are based on management’s belief or interpretation. All statements contained in this announcement that do not relate to matters of historical fact should be considered forward-looking statements. In certain cases, forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved.” Forward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of the Company to control or predict, that may cause their actual results, performance or achievements to be materially different from those expressed or implied thereby, and are developed based on assumptions about such risks, uncertainties and other factors set out herein.
Reference should be made to those documents that Biodexa shall file from time to time or announcements that may be made by Biodexa in accordance with the rules and regulations promulgated by the SEC, which contain and identify other important factors that could cause actual results to differ materially from those contained in any projections or forward-looking statements. These forward-looking statements speak only as of the date of this announcement. All subsequent written and oral forward-looking statements by or concerning Biodexa are expressly qualified in their entirety by the cautionary statements above. Except as may be required under relevant laws in the United States, Biodexa does not undertake any obligation to publicly update or revise any forward-looking statements because of new information, future events or events otherwise arising.
